Does Benzodiazepine Withdrawal Cause Weight Loss? Weight Changes During a Klonopin or Xanax Taper

Does benzodiazepine withdrawal cause weight loss?

Yes, it can, and it can also do the opposite. The Ashton Manual, written by Professor C. Heather Ashton, lists “Appetite/weight change” in Chapter III, Table 1, among the physical symptoms of benzodiazepine withdrawal, alongside nausea, vomiting, diarrhea and other digestive complaints. Professor Ashton wrote that considerable weight loss, eight to ten pounds or more, sometimes occurs in withdrawal, and that some people gain weight instead.

She also wrote something reassuring. Weight changes in withdrawal are not severe enough to worry about, and normal weight is soon regained once the taper is over. That sentence matters, because most of what is written about benzodiazepines and weight gets the mechanism wrong and the advice backwards.

So, why does the weight come off?

Appetite and digestion drive the weight loss, not metabolism.

A person tapering a benzodiazepine often eats less because eating has become difficult. Nausea, vomiting, diarrhea, abdominal pain and bloating all appear on the Manual’s list of physical symptoms, and a stomach that hurts does not ask for dinner. Anxiety takes the rest of the appetite, and poor sleep takes the energy to shop and cook.

Professor Ashton also suggested that a rebound effect on appetite may be at work, since benzodiazepines can increase appetite while they are taken, and withdrawal would then be the mirror image. The United States Food and Drug Administration (FDA) says the same in its 2020 benzodiazepine label update, which lists gastrointestinal reactions, including nausea, vomiting, diarrhea, weight loss and decreased appetite, among the acute withdrawal signs. None of these sources describes a change in metabolic rate.

Much of what is written online blames a “slowed” or “sped up” metabolism. No citable source documents any such change. Withdrawal changes whether the person can eat.

Some people gain weight instead.

The Manual says plainly that some people gain weight in withdrawal, and Dr. Mark Leeds sees the same pattern in his Fort Lauderdale practice. The usual story is appetite returning after the worst of the nausea, comfort eating against anxiety, and far less activity, because fatigue and poor sleep keep a person on the couch. Both directions come from the same nervous system trying to find its footing.

Neither direction is a reason to change the pace of a taper. Weight that comes off because of nausea comes back when the nausea settles, and weight that comes on during a long, tired stretch comes off when energy returns. The taper is planned around the nervous system, not the scale.

Klonopin (clonazepam) can move weight in either direction.

Klonopin’s own prescribing information lists anorexia, meaning loss of appetite, and increased appetite, and weight loss and weight gain, among its adverse reactions, and its panic-disorder trials separately recorded decreased appetite. In other words, the drug itself pushes weight both ways in different people. The label’s warnings, updated with the 2020 class labeling, then place weight loss and decreased appetite among the acute withdrawal signs.

Clonazepam is a long-acting drug, with a half-life of roughly thirty to forty hours, so its blood level falls more smoothly between doses than a short-acting drug’s. Yet, withdrawal from it is still real, and nausea, vomiting, diarrhea and appetite loss are what usually drive weight down during a clonazepam taper. When appetite is poor, small frequent meals, soups, smoothies and other easy-to-digest foods, and plenty of fluids keep the body fed while the digestive system calms.

Dr. Leeds asks patients to note weight and appetite between visits, the same way they note sleep and anxiety. Rapid loss is a signal to slow or hold, not to push through.

Xanax (alprazolam) is short-acting, and that changes the picture.

Alprazolam leaves the body quickly. Its label gives a mean half-life of about eleven hours, though it reports a longer half-life in people with obesity, probably because the drug lingers in body fat. The label also describes interdose symptoms, meaning early-morning anxiety and anxiety emerging between doses, in patients taking their prescribed maintenance dose. Add a missed dose or a cut that is too large and the withdrawal arrives sharply, nausea and appetite loss included.

For potent, short-acting drugs like alprazolam, Chapter II of the Ashton Manual advises switching to diazepam, a long-acting benzodiazepine that is eliminated slowly, so that the blood level falls in a smooth, gradual line. That switch is the crossover taper, and Dr. Leeds uses it where it helps a patient, following the Ashton Manual. The Manual’s one named exception is triazolam (Halcion), which Professor Ashton wrote can be stopped without substitution because it is eliminated within a day. Dr. Leeds still prefers a gradual taper there, consistent with that drug’s label, and alprazolam is not that exception.

The 2020 FDA update also says physical dependence can develop within days to weeks of steady use, even as prescribed, and that stopping abruptly or cutting too fast can cause withdrawal reactions, including seizures, that can be life-threatening. Anyone who has a seizure, or any medical emergency, should call 911. The Xanax label itself calls for a gradual taper, caps how fast the dose may fall, and adds that some patients need slower still.

Dieting during a taper is the wrong response.

Withdrawal weight loss is like the weight lost during a bad flu. It comes off because the body is unwell, it comes back when the body is well, and nobody diets during a flu. A restrictive diet on top of nausea and poor appetite simply starves a nervous system that needs steady fuel.

Weight-loss drugs and fat-loss supplements are worse than useless here. Many are stimulants, and a stimulant poured into a nervous system already running hot brings more anxiety, more tremor, worse sleep and a faster heartbeat, the very symptoms the taper is trying to quiet. Herbal calmers and sleep aids deserve a conversation with the prescriber first, since some act on the same gamma-aminobutyric acid (GABA) receptors as the drug being tapered.

Alcohol belongs in the same conversation. The FDA’s 2020 communication says plainly not to drink alcohol with benzodiazepines, and alcohol acts on the same GABA system, so it muddies the taper. Caffeine is a smaller matter. The Ashton Manual allows coffee or tea in moderation, about two cups a day, and Dr. Leeds’ practice keeps it there, since more than that can sharpen anxiety, tremor and poor sleep.

When should a patient call the prescriber?

Some weight loss is expected. Rapid loss is not, and a patient whose clothes are noticeably looser after two or three weeks, who cannot keep fluids down, or who feels dizzy on standing and passes little urine should call the prescriber that day. Dehydration from vomiting and diarrhea is the common medical problem hiding inside “withdrawal weight loss.”

A history of disordered eating deserves a mention at the very first visit, before the taper begins. Restriction can quietly reawaken when appetite falls, and a prescriber who knows the history can watch for it and slow down. Call 911 for a seizure, fainting, confusion or an inability to keep fluids down for more than a day, and anyone with thoughts of suicide can call or text 988, the Suicide and Crisis Lifeline, at any hour.

A slow taper limits the swing.

Fortunately, the taper that protects the nervous system also protects the appetite. Chapter II of the Ashton Manual describes small steps, up to about a tenth of the current dose, held for a week or two before the next, and it says plainly that there is no need to hurry and that many people take a year or more. The Maudsley Deprescribing Guidelines refine the shape with hyperbolic reductions, steps that shrink as the dose gets lower, because the last small doses do more work at the receptor than the first large ones.

The pace belongs to the patient. If nausea and appetite loss surge after a cut, the dose is held until they settle. If a step passes quietly, patient and doctor may agree to take the next one. Nothing about the scale sets the schedule, and no schedule in an article should replace the one worked out with a prescriber.

This is also where the language needs correcting. A person losing weight during a prescribed benzodiazepine taper is not kicking a habit. Physical dependence is not addiction. Dependence is a medical condition produced by the prescription itself, and its treatment is a gradual, medically supervised taper over months, sometimes longer, adapted to the person.

Dr. Leeds’ practice treats weight as a symptom to watch, not a schedule to follow.

Dr. Leeds is an osteopathic physician and deprescribing specialist in Fort Lauderdale, Florida, and his practice offers one service: medically supervised benzodiazepine and z-drug tapering, by concierge arrangement, for patients in Florida. He also helps patients taper other psychiatric medications. Informed consent in his practice means risks first, the alternatives, an exit plan from the first visit, and the right to decline at any point.

In Dr. Leeds’ practice, weight and appetite are tracked between visits alongside sleep and anxiety, the crossover to diazepam is used where it helps, and the step size and the holds follow the patient’s symptoms rather than a calendar. Weight lost to withdrawal returns, as Professor Ashton wrote, once the taper is done. Contact Dr. Leeds to ask whether a supervised taper is the right next step.

This article is educational. It is not medical advice, and reading it does not create a doctor-patient relationship. Decisions about starting, continuing, or tapering any medication should be made with your own physician.